Alzheimer-specialist Probiodrug AG last week not only obtained a new US patent covering the inhibition of the enzyme glutaminyl cyclase (QC) for the treatment of CNS diseases. The company also announced the appointment of Dr Claus Braestrup, former President & CEO of Lundbeck A/S to Chairman of the Supervisory Board and Prof Dr Lennart Mucke, Director of the Gladstone Institute of Neurological Disease in San Francisco, Calif. to its Scientific Advisory Board.  Moreover, the company was awarded the “IQ Innovationspreis Mitteldeutschland” by the Industrial Initiative for Central Germany for its innovative therapeutic strategy to combat Alzheimer’s disease. In May, Probiodrug hosted the PSP 2010 conference with more than 150 scientists to discuss its approach.